FDA-Recognized Treatment
How HBOT Accelerates Wound Healing
Hyperbaric oxygen therapy (HBOT) supports wound healing by delivering concentrated oxygen under pressure directly into blood plasma, increasing oxygen levels in damaged tissue. This increased oxygen promotes angiogenesis (new blood vessel formation), stimulates collagen production, and enhances white blood cell function to fight infection. Wound healing is among the 14 FDA-recognized indications for HBOT, and the therapy has been the subject of over 10,000 clinical studies.
Chronic wounds fail to heal because the damaged tissue lacks adequate blood supply and oxygen. Without oxygen, cells cannot produce the energy needed for repair, collagen cannot form properly, and immune cells cannot effectively combat bacteria. HBOT breaks this cycle by dissolving oxygen directly into plasma under pressure, allowing it to reach ischemic tissue that red blood cells cannot access through compromised blood vessels.
The scientific evidence for HBOT in wound care is substantial. Systematic reviews published in Diabetes Care have reported higher wound closure rates in patients receiving HBOT compared to standard care alone. A Cochrane Review concluded that HBOT may reduce the risk of major amputation in diabetic foot ulcer patients. These findings have contributed to HBOT being incorporated into advanced wound healing protocols at hospitals and wound care centers worldwide.
HBOT Wound Healing Statistics
The Science
How Oxygen Heals Wounds at the Cellular Level
Angiogenesis
Research indicates HBOT stimulates the growth of new blood vessels (angiogenesis) in the wound bed. These new capillaries deliver oxygen and nutrients to tissue that was previously starved, supporting the vascular infrastructure necessary for wound closure.
Collagen Synthesis
Oxygen is a required substrate for collagen production. HBOT provides the oxygen that fibroblasts need to synthesize collagen, the structural protein essential for building new connective tissue and closing wounds.
Immune Enhancement
White blood cells require oxygen to produce the reactive oxygen species that kill bacteria. Research shows HBOT may enhance leukocyte bactericidal activity, supporting the body in clearing infection from chronic wound beds that resist standard antibiotic therapy.
Edema Reduction
Hyperbaric oxygen causes vasoconstriction that reduces edema and swelling around the wound while simultaneously increasing the amount of oxygen dissolved in plasma. This reduces tissue pressure and improves circulation to the wound.
Stem Cell Mobilization
A study published in the American Journal of Physiology (Thom et al., 2006) reported that HBOT significantly increased circulating stem/progenitor cells in human subjects. These stem cells may migrate to wound sites and differentiate into the cell types needed for tissue repair.
Growth Factor Release
Research indicates HBOT may stimulate the release of vascular endothelial growth factor (VEGF) and other growth factors that coordinate the complex biological processes involved in wound repair and tissue regeneration.
Clinical Applications
Wound Types Treated with HBOT
Wound healing is one of the most well-established medical applications of hyperbaric oxygen therapy and is among the FDA-recognized indications. The following wound types have been studied extensively in the context of HBOT as part of a comprehensive wound care protocol.
Diabetic Foot and Lower Extremity Ulcers
One of the most common FDA-cleared indications for HBOT in wound care. Diabetic wounds suffer from reduced blood flow and impaired immune function. HBOT is used to increase tissue oxygenation and support white blood cell activity. Medicare covers HBOT for Wagner grade III or higher diabetic wounds that have not responded to 30 days of standard care.
Radiation Tissue Damage
Radiation therapy can cause delayed tissue damage (osteoradionecrosis and soft tissue radionecrosis) months or years after treatment. HBOT is used to promote new blood vessel growth in radiation-damaged tissue, supporting oxygen and nutrient delivery. This is one of the most evidence-supported FDA-cleared applications of HBOT, with protocols of 30 to 60 sessions studied in clinical settings.
Compromised Skin Grafts and Flaps
When skin grafts or surgical flaps show signs of compromise due to inadequate blood supply, HBOT may improve graft survival by increasing oxygen delivery to the transplanted tissue. Clinical experience suggests early intervention with HBOT may help support graft viability.
Chronic Non-Healing Wounds
Wounds that have not responded to at least 30 days of standard treatment may benefit from HBOT. By addressing the underlying oxygen deficit in the wound bed, HBOT may help support the healing process in wounds that have stalled in the inflammatory phase.
Crush Injuries and Compartment Syndrome
Severe crush injuries cause swelling that restricts blood flow and damages tissue. HBOT is used in these cases to help reduce edema through hyperoxic vasoconstriction while maintaining increased oxygen delivery, with the goal of preserving tissue viability.
Necrotizing Soft Tissue Infections
Aggressive infections that destroy soft tissue are among the FDA-cleared indications for HBOT. The therapy is used alongside surgical debridement and antibiotics as part of a comprehensive treatment approach, potentially supporting immune function through increased oxygenation.
For Wound Care Clinics
The Ideal Chamber for Clinical Wound Care
Fortius 420
The Fortius 420 is OxyHealth's clinical-grade hyperbaric chamber, purpose-built for wound care centers, hospitals, and medical clinics. With higher pressurization capability, a durable steel-frame design, and spacious interior for patient comfort, the Fortius 420 delivers the performance and reliability that wound care programs demand. FDA-cleared and ISO 13485 certified, it integrates seamlessly into established wound care protocols.
FDA Cleared
510(k)
ISO 13485
Certified
Clinical Grade
Pressurization
High Volume
Durability
Frequently Asked Questions
HBOT for Wound Healing FAQ
Hyperbaric oxygen therapy is FDA-recognized for several wound-related conditions. The FDA has identified 14 conditions for which HBOT is recognized, including diabetic lower extremity wounds, chronic refractory osteomyelitis, compromised skin grafts and flaps, crush injuries, and delayed radiation injury (soft tissue and bony necrosis). The Undersea and Hyperbaric Medical Society (UHMS) also maintains a list of approved indications. OxyHealth chambers are FDA-cleared (510(k)) medical devices, providing confidence that the equipment meets rigorous safety and efficacy standards.
The number of HBOT sessions required depends on the wound type, severity, and individual patient response. For diabetic foot ulcers, treatment protocols typically involve 20 to 40 sessions, each lasting 90 minutes at 2.0 to 2.4 ATA. Radiation tissue injury may require 30 to 60 sessions. Acute traumatic wounds and compromised grafts may respond within 10 to 20 sessions. Most wound care protocols schedule sessions once or twice daily, five days a week. Your wound care specialist will monitor progress and adjust the treatment plan based on healing response.
HBOT has been studied for a wide range of wound types, several of which are among the FDA-recognized indications for HBOT. These include diabetic foot and lower extremity ulcers, venous stasis ulcers, arterial insufficiency ulcers, pressure injuries (bedsores), surgical wound dehiscence, radiation-damaged tissue (osteoradionecrosis and soft tissue radionecrosis), compromised skin grafts and flaps, crush injuries with compartment syndrome, necrotizing soft tissue infections, and chronic refractory osteomyelitis. The therapy is often considered for wounds that have not responded to standard treatments over a period of 30 days or more.
Oxygen plays a critical role in nearly every phase of wound healing. At the cellular level, HBOT promotes angiogenesis, which is the formation of new blood vessels that deliver nutrients and oxygen to the wound bed. It stimulates fibroblast proliferation and collagen synthesis, essential for building new connective tissue. HBOT enhances white blood cell bactericidal activity, helping fight infection in the wound. It also reduces edema and inflammation by constricting blood vessels while simultaneously increasing oxygen delivery. Research in hyperbaric medicine indicates that HBOT can increase tissue oxygen levels significantly, creating an environment that supports every stage of healing from inflammation through remodeling.
Many insurance providers, including Medicare, cover HBOT for specific FDA-recognized wound conditions. Medicare covers HBOT for diabetic wounds of the lower extremities (Wagner grade III or higher) that have not improved after 30 days of standard wound care. Coverage typically requires documentation from a wound care physician and evidence that the wound has failed conventional therapy. Private insurance coverage varies by plan and provider but generally follows similar criteria. OxyHealth recommends working with your wound care facility and insurance provider to verify coverage. Some clinics also offer self-pay options for patients whose conditions are not covered.
Clinical outcomes for HBOT in wound healing are well-documented. A systematic review published in Diabetes Care found that HBOT significantly increased the rate of healed diabetic foot ulcers compared to standard care alone. Patients often observe reduced wound drainage and inflammation within the first 5 to 10 sessions. New tissue growth (granulation) typically becomes visible after 10 to 15 sessions. Complete wound closure depends on the wound type and severity, but many chronic wounds that failed to respond to months of standard treatment show meaningful improvement within a 30 to 40 session HBOT protocol. Post-radiation patients frequently report significant pain reduction and improved tissue quality.
Research supports the role of HBOT in reducing amputation rates among diabetic patients with non-healing lower extremity wounds. A Cochrane Review analysis concluded that HBOT significantly reduces the risk of major amputation in patients with diabetic foot ulcers. By promoting angiogenesis and tissue oxygenation in ischemic wound beds, HBOT helps restore the healing environment necessary for wound closure. The therapy is most effective when used as part of a comprehensive wound care program that includes debridement, offloading, infection management, and blood sugar control.
Yes, HBOT is considered safe for patients with diabetes when administered under appropriate medical supervision. The primary consideration is blood glucose management, as HBOT sessions can affect blood sugar levels. Patients should monitor their glucose before and after sessions and communicate with their care team about any adjustments to medications. OxyHealth chambers are designed with safety features including pressure relief valves, clear viewing windows for patient monitoring, and easy-access entry and exit. Over decades of clinical use, HBOT has maintained an excellent safety profile for diabetic patients.
Learn More